Former President Donald Trump is curbing his support of a controversial drug pricing plan that rose concerns among pharmaceutical executives while he was in office, STAT News’ Rachel Cohrs Zhang
Former President Donald Trump is curbing his support of a controversial drug pricing plan that rose concerns among pharmaceutical executives while he was in office, STAT News’ Rachel Cohrs Zhang
Goldman Sachs analyst James Quigley maintained a Hold rating on Novartis AG (NOVN – Research Report) today and set a price target of CHF104.00. Quigley covers the Healthcare sector, focusing
Analyst Eric Le Berrigaud from Stifel Nicolaus maintained a Hold rating on Novartis AG (NOVN – Research Report) and keeping the price target at CHF106.00. Eric Le Berrigaud has given
Barclays analyst Emily Field maintained a Sell rating on Novartis AG (NOVN – Research Report) today and set a price target of CHF85.00. Field covers the Healthcare sector, focusing on
Pfizer (